Head-to-head trials of systemic psoriasis therapies: A systematic review of study design and maximum acceptable treatment differences.

Por Wan, M. T., Alvarez, J., Shin, D. B., Dommasch, E. D., Wu, J. J., Gelfand, J. M.
Publicado no J Eur Acad Dermatol Venereol (2018)

Real‐life effectiveness of once‐daily calcipotriol and betamethasone dipropionate gel vs. ointment formulations in psoriasis vulgaris: final analysis of the 52‐week PRO‐long study...

Por Lambert, J., Hol, C.W., Vink, J.
Publicado no J Eur Acad Dermatol Venereol (2015)

Measurement of Tanning Dependence

Por Heckman, C.J., Darlow, S., Kloss, J.D., Cohen-Filipic, J., Manne, S.L., Munshi, T., Yaroch, A.L., Perlis, C.
Publicado em 2013

Safety and efficacy of apremilast through 104 weeks in patients with moderate to severe psoriasis who continued on apremilast or switched from etanercept treatment: findings from t...

Por Reich, K., Gooderham, M., Bewley, A., Green, L., Soung, J., Petric, R., Marcsisin, J., Cirulli, J., Chen, R., Piguet, V.
Publicado no J Eur Acad Dermatol Venereol (2018)

Increased prevalence of HCV and hepatic decompensation in adults with psoriasis: a population-based study in the United Kingdom

Por Noe, M. H., Grewal, S. K., Shin, D. B., Ogdie, A., Takeshita, J., Gelfand, J. M.
Publicado no J Eur Acad Dermatol Venereol (2017)

The role of IL‐23 and the IL‐23/T(H)17 immune axis in the pathogenesis and treatment of psoriasis

Por Girolomoni, G., Strohal, R., Puig, L., Bachelez, H., Barker, J., Boehncke, W.H., Prinz, J.C.
Publicado no J Eur Acad Dermatol Venereol (2017)

Initiation of TNF Inhibitor Therapy and Change in Physiologic Measures in Psoriasis

Por Wu, Jashin J., Liu, Liyan, Asgari, Maryam M., Curtis, Jeffrey R., Harrold, Leslie, Salman, Craig, Herrinton, Lisa J.
Publicado em 2013

The three moments of skin cream application: an evidence‐based proposal for use of skin creams in the prevention of irritant contact dermatitis in the workplace

Por Hines, J., Wilkinson, S.M., John, S.M., Diepgen, T.L., English, J., Rustemeyer, T., Wassilew, S., Kezic, S., Maibach, H.I.
Publicado no J Eur Acad Dermatol Venereol (2016)

Granuloma annulare associated with immune checkpoint inhibitors

Por Wu, J., Kwong, B.Y., Martires, K.J., Rieger, K.E., Chung, W.H., Iyer, G.V., Lacouture, M.E.
Publicado no J Eur Acad Dermatol Venereol (2017)

The Epidermolysis Bullosa Disease Activity and Scarring Index (EBDASI): grading disease severity and assessing responsiveness to clinical change in epidermolysis bullosa

Por Jain, S.V., Harris, A.G., Su, J.C., Orchard, D., Warren, L.J., McManus, H., Murrell, D.F.
Publicado no J Eur Acad Dermatol Venereol (2016)

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III r...

Por Gottlieb, A.B., Lacour, J.‐P., Korman, N., Wilhelm, S., Dutronc, Y., Schacht, A., Erickson, J., Zhang, L., Mallbris, L., Gerdes, S.
Publicado no J Eur Acad Dermatol Venereol (2016)

A Randomized, blinded assessor study to Evaluate the efFIcacy and safety of etanercept 50 mg once weekly plus as Needed topical agent vs. Etanercept 50 mg twice weekly in patients...

Por Papp, KA, Barber, K, Bissonnette, R, Bourcier, M, Lynde, CW, Poulin, Y, Shelton, J, Toole, J, Vieira, A, Poulin-Costello, M
Publicado no J Eur Acad Dermatol Venereol (2015)

Shifting the focus – the primary role of IL‐23 in psoriasis and other inflammatory disorders

Por Gooderham, M.J., Papp, K.A., Lynde, C.W.
Publicado no J Eur Acad Dermatol Venereol (2018)

Efficacy and safety of adalimumab in Chinese patients with moderate‐to‐severe plaque psoriasis: results from a phase 3, randomized, placebo‐controlled, double‐blind study

Por Cai, L., Gu, J., Zheng, J., Zheng, M., Wang, G., Xi, L.‐Y., Hao, F., Liu, X.‐M., Sun, Q.‐N., Wang, Y., Lai, W., Fang, H., Tu, Y.‐T., Sun, Q., Chen, J., Gao, X.‐H., Gu, Y., Teixeira, H.D., Zhang, J.‐Z., Okun, M.M.
Publicado no J Eur Acad Dermatol Venereol (2016)

Depression and the risk of psoriasis in US women

Por Dominguez, PL, Han, J, Li, T, Ascherio, A, Qureshi, AA
Publicado em 2012

A patient‐centred approach to biological treatment decision making for psoriasis: an expert consensus

Por Strohal, R., Prinz, J. C., Girolomoni, G., Nast, A.
Publicado no J Eur Acad Dermatol Venereol (2015)

Public primary and secondary skin cancer prevention, perceptions and knowledge: an international cross‐sectional survey

Por Seité, S., del Marmol, V., Moyal, D., Friedman, A.J.
Publicado no J Eur Acad Dermatol Venereol (2017)

Improvements in patient‐reported outcomes in patients with psoriasis receiving etanercept plus topical therapies: results from REFINE

Por Papp, K.A., Barber, K., Bissonnette, R., Bourcier, M., Lynde, C.W., Poulin, Y., Shelton, J., Garces, K., Toole, J., Poulin‐Costello, M.
Publicado no J Eur Acad Dermatol Venereol (2015)

The efficacy and safety of apremilast, etanercept and placebo in patients with moderate‐to‐severe plaque psoriasis: 52‐week results from a phase IIIb, randomized, placebo‐controlle...

Por Reich, K., Gooderham, M., Green, L., Bewley, A., Zhang, Z., Khanskaya, I., Day, R.M., Goncalves, J., Shah, K., Piguet, V., Soung, J.
Publicado no J Eur Acad Dermatol Venereol (2016)

Host risk factors for the development of multiple non-melanoma skin cancers

Por Qureshi, A.A., Wei-Passanese, E.X., Li, T., Han, J.
Publicado em 2012